Thymic stromal lymphopoietin (TSLP) is an interleukin (IL) 7-like cytokine that triggers dendritic cell-mediated T helper (Th)2 infl ammatory responses. TSLP is highly expressed by keratinocytes in skin lesions of patients with atopic dermatitis and is associated with dendritic cell activation in situ, suggesting that TSLP might be a master switch for allergic infl ammation at the epithelial cell-dendritic cell interface. New reports now establish a direct link between TSLP expression and the pathogenesis of atopic dermatitis and asthma in vivo, and begin to reveal the molecular mechanisms underlying TSLP-induced allergic infl ammation.
Thymic stromal lymphopoietin (TSLP) is a novel IL-7-like cytokine, origi nally cloned from a murine thymic stromal cell line, that supports the growth and diff erentiation of B cells and the proliferation of T cells (1, 2) . The TLSP receptor (TLSPR) is heterodimeric, consisting of the IL-7R-α chain and a common γ receptor-like chain (TSLPR-γ) (3) (4) (5) (6) .
Human TSLP and TSLPR were cloned in 2001 by computational analyses of human genomic data (7, 8) . The early human studies were initially frustrating because human recombinant TSLP (hTSLP), unlike mouse TSLP, did not support the development or activation of B and T cells. Surprisingly, our group found that hTSLP instead potently activated immature CD11c + myeloid dendritic cells (mDCs) (7, 9) . TSLP-activated DCs induced robust proliferation of naive allogeneic CD4 + T cells, which subsequently diff erentiated into Th2 cells that produced the allergypromoting cytokines IL-4, IL-5, IL-13, and TNF, but did not produce IL-10 or interferon-γ (9) .
In vivo, TSLP was shown to be highly expressed by keratinocytes in atopic dermatitis lesions and its express ion was associated with the migration and activation of Langerhans cells, suggesting for the fi rst time that TSLP might be an early trigger for DC-mediated allergic infl ammation (9) . Human TSLP was later found to be expressed by epithelial cells in peripheral mucosalassociated lymphoid tissue, where it activates mDCs to induce homeostatic proliferation of naive and memory CD4 + T cells in the periphery (10, 11) . TSLP is also produced by Hassall's corpuscles in the human thymus, where it instructs thymic DCs to convert high affi nity self-reactive T cells into CD4 + CD25 + Foxp3 + regulatory T cells (12) .
In this commentary, we will review the recent progress in understanding the role of TSLP in the development of atopy and the underlying molecular mechanisms that govern this process.
TSLP-activated DCs create a Th2-permissive microenvironment
Like all stimuli that activate mDCs, including CD40L and Toll-like receptor (TLR) ligands, such as bacterial lipopolysaccharide (LPS), poly I:C, and R848, TSLP strongly up-regulates the expression of MHC class II, CD54, CD80, CD83, CD86, and DC-lamp on human mDCs. However, unlike CD40L and TLR ligands, TSLP does not stimulate mDCs to produce the Th1-polarizing cytokine IL-12 or the proinfl ammatory cytokines TNF, IL-1β, and IL-6 (9). Our recent gene expression analyses of TSLP-activated DCs confi rm and extend this fi nding by showing that TSLP does not induce the expression of mRNA encoding the IL-12 family members IL-12, IL-23, and IL-27, nor that of mRNA encoding the type I IFNs-all cytokines that induce Th1 diff erentiation (13) . Interestingly, TSLP treatment caused mDCs to produce large amounts of the chemokines IL-8 and eotaxin-2, which attract neutrophils and eosinophils, as well as TARC and MDC, which attract Th2 cells (unpublished data). We suggest that the inability of TSLP to induce the production of Th1-polarizing cytokines by mDCs is one of the most important features of TSLP-activated DCs, and helps these cells create a Th2-permissive microenvironment. The molecular mechanisms underlying TSLP's ability to promote mDC maturation without inducing the production of Th1-polarizing cytokines are unknown. TSLP appears to activate a unique signaling pathway in mDCs that is independent of the transcription factor NF-κB and the TLR adaptor protein MyD88, both of which are required for the response to Th1-promoting stimuli. This hypothesis is supported by the fact that TSLP activates STAT5 in myeloid cells (7, 14) although the signaling molecules that function upstream and downstream of STAT5 in this pathway are currently unknown. In contrast, neither TLR ligands nor CD40L appear to activate STAT5 in mDCs.
TSLP-DCs induce infl ammatory Th2 cells
In most immunology textbooks and literature, Th2 cells are defi ned as CD4 + T cells that produce IL-4, IL-5, IL-13, and IL-10, and Th1 cells such as CD4 + T cells that produce IFN-γ and sometimes TNF. When TSLP-DCs are used to stimulate naive allogeneic CD4 + T cells in vitro, they induce a unique type of Th2 cell that produces the classical Th2 cytokines IL-4, IL-5, and IL-13, the developing Th2 cells synergized with the OX40L-derived signals to further promote Th2 cell development. We thus conclude that TSLP-activated DCs create a Th2-permissive microenvironment by up-regulating OX40L without inducing the production of Th1-polarizing cytokines. The dominance of IL-12 over OX40L may provide a molecular explanation for the hygiene theory, which proposes that microbial infections that trigger Th1 responses may decrease the subsequent development of Th2-driven atopy.
The association of TSLP with atopic dermatitis and asthma
Early studies showed that TSLP mRNA was highly expressed by human primary skin keratinocytes, bronchial epithelial cells, smooth muscle cells, and lung fibroblasts, but not by most hematopoietic cells, including B cells, T cells, NK cells, granulocytes, macrophages, monocytes, and DCs. Interestingly, mast cells and large amounts of TNF, but little or no IL-10 (9). Although not typically considered a Th2 cytokine, TNF is prominent in asthmatic airways, and genotypes that correlate with increased TNF secretion are associated with an increased risk of asthma (15, 16) , suggesting that TNF plays an important role in the development of asthma and allergic infl ammation.
In addition to inducing the production of Th2 cytokines and TNF, CD4 + T cells activated by TSLP-stimulated DCs produce decreased levels of IL-10 and IFN-γ, two cytokines known to down-regulate Th2 cell infl ammation (17) . IL-10, although initially classifi ed as a Th2 cytokine, counteracts infl ammation and is produced at decreased levels in bronchoalveolar lavage fl uid from atopic patients compared with normal subjects (18) . In addition, recent studies showed that DC-or T cellderived IL-10 prevents airway hypersensitivity after allergen exposure (19, 20) .
Because of their unique profi le of cytokine production, we propose that Th2 cells induced by TSLP-activated DCs be called infl ammatory Th2 cells. The pathogenic T cells involved in allergic diseases such as atopic dermatitis and asthma are likely to be infl ammatory Th2 cells. Conventional Th2 cells that produce IL-4, IL-5, IL-13, and IL-10, but little TNF may not be involved in promoting allergic diseases but are induced in many circumstances, including when antigen-presenting cells or T cells are treated with im munosuppressive drugs, and when T cells are triggered by low affi nity TCR ligands (21) (22) (23) .
OX40 ligand promotes the differentiation of infl ammatory Th2 cells
In an attempt to identify the molecular mechanism by which TSLP-activated DCs induce naive CD4 + T cells to differentiate into TNF-producing infl ammatory Th2 cells, our group performed gene expression analysis on immature human mDCs that were either resting or were activated by TSLP, poly I:C, or CD40L. This analysis, reported in a recent issue of JEM, showed that only TSLP induces human mDCs to express the TNF superfamily protein OX40L at both the mRNA and protein level (13) .
The expression of OX40L by TSLPDCs was important for the induction of infl ammatory Th2 cells, as blocking OX40L with a neutralizing antibody inhibited the production of Th2 cytokines and TNF, and enhanced the production of IL-10, by the CD4 + T cells. Consistent with these results, we found that treating naive T cells with recombinant OX40L promoted the production of TNF but inhibited the production of IL-10. In other words, signals triggered by OX40L induced the generation of infl ammatory Th2 cells.
OX40L-induced infl ammatory Th2 cell diff erentiation depended on the absence of IL-12, as OX40L lost the ability to trigger infl ammatory Th2 cell diff erentiation in the presence of IL-12. The ability of OX40L to trigger Th2 cell development was independent of IL-4, although the IL-4 that was produced by activated by IgE receptor cross-linking expressed high levels of TSLP, suggesting an additional cell type that may help trigger allergic infl ammation. TSLP protein, examined by immunohistology on cryopreserved tissue sections, is undetectable in normal skin or nonlesional skin in patients with atopic dermatitis, but is highly expressed in acute and chronic atopic dermatitis lesions (9) . TSLP is expressed mainly in keratinocytes of the apical layers of the epidermis, suggesting that TSLP production is a feature of fully diff erentiated keratinocytes (Fig. 1) . TSLP was not found in skin lesions from patients with nickelinduced contact dermatitis or disseminated lupus erythematosus. Interestingly, TSLP expression in patients with atopic dermatitis was associated with Langerhans cell migration and activation in situ (Fig. 1) , suggesting that TSLP may contribute directly to the activation of these cells, which could then migrate into the draining lymph nodes and prime allergenspecifi c Th2 responses (9) .
A more recent study showed by in situ hybridization that TSLP expression was increased in asthmatic airways and correlated with both the expression of Th2-attracting chemokines and with disease severity (24) , providing the fi rst link between TSLP and human asthma.
TSLP triggers atopic dermatitis and asthma in mice
Our own attempts to demonstrate the function of TSLP in mice were unsuccessful, leading us to believe that TSLP may function diff erently in humans and mice. But reports from three laboratories now reveal that TSLP and TSLPR also play a critical role in the initiation of allergic diseases in mice.
In a recent issue of JEM, Yoo et al. demonstrated that mice engineered to overexpress TSLP in the skin developed atopic dermatitis characterized by eczematous skin lesions containing infl ammatory cell infi ltrates, a dramatic increase in circulating Th2 cells and elevated serum IgE (25) . This study also suggested that TSLP may directly activate DCs in mice. In another study, Li et al. reported the surprising fi nding that selective ablation of retinoid X receptors (RXRs) in epidermal keratinocytes triggered atopic dermatitis in mice (26) . The authors of that study noted that TSLP expression was rapidly induced in skin keritinocytes that lacked RXRs, likely contributing to the development of disease. This group confi rmed the fi nding that transgenic mice overexpressing TSLP in the skin developed atopic dermatitis, thus solidifying the link between TSLP and the development of atopic dermatitis.
Two recent studies also formally established a critical role of TSLP in the initiation of asthma in vivo. Zhou et al. showed that lung-specifi c expression of a TSLP transgene induced allergic airway infl ammation (asthma) characterized by a massive infi ltration of leukocytes (including Th2 cells), goblet cell hyperplasia, and subepithelial fi brosis, as well as increased serum IgE levels (27) . In contrast, mice lacking TSLPR failed to develop asthma in response to inhaled antigens (27, 28) . Together, these studies demonstrate that TSLP is required for the initiation of allergic airway infl ammation in mice.
Conclusion and future perspective
We now know that TSLP is highly expressed by skin keratinocytes and airway epithelial cells during allergic infl ammation (Fig. 2) , but how TSLP expression is triggered in these cells-by allergen exposure or virus infection-remains unclear. As the expression of RXRs in skin keratinocytes may actively suppress TSLP production under normal physiological conditions, further studies on the regulation of these receptors may provide important clues as to how allergen or viral infection triggers TSLP production.
TSLP instructs mDCs to induce infl ammatory Th2 cells in two ways (Fig.  2) . First, TSLP induces DC maturation without driving the production of the Th1-polarizing cytokine IL-12, thus creating a Th2-permissive microenvironment. Second, TSLP induces the expression of OX40L on DCs, which directly triggers the diff erentiation of infl ammatory Th2 cells. The signaling pathway that is triggered by TSLP and leads to this unique Th2 phenotype is unknown, but it appears to involve STAT5 activation, independent of the classical NF-κB and myD88 signaling pathways.
OX40L signaling has several important features. It triggers Th2 polarization independent of IL-4, promotes TNF production, and inhibits IL-10 production by the developing Th2 cells, but only in the absence of IL-12. In the presence of IL-12, OX40L signaling instead promotes the development of Th1 cells that, like infl ammatory Th2 cells, produce TNF, but not IL-10. This fi nding may help explain why blocking OX40-OX40L interaction reduces the severity of Th1-mediated autoimmune diseases (29)-the reason some immunologists are reluctant to accept OX40L as a Th2 polarizing factor. We now believe that this inhibition of Th1-induced pathology is caused by the increased production of the immunosuppressive cytokine IL-10 and the decreased production of the infl ammation-promoting cytokine TNF that results from blocking OX40-OX40L interactions.
Based on these recent studies, we propose the subdivision of Th2 cells into infl ammatory Th2 cells that produce high levels of TNF but little IL-10, and conventional Th2 cells that produce little TNF but high levels of IL-10. Infl ammatory Th2 cells, but not conventional Th2 cells, may be involved in allergic infl ammatory diseases.
Our initial fi nding that epithelial cell-derived TSLP triggers DC-mediated infl ammatory Th2 responses in humans, together with the exiting in vivo studies reported in the last few months, suggest that TSLP represents a master switch of allergic infl ammation at the epithelial cell-DC interface. TSLP should therefore be considered as a target for immunological intervention in the treatment of allergic diseases.
